安徽华恒生物科技股份有限公司 2025 年第三次临时股东会会议资料 证券代码：688639 证券简称：华恒生物 安徽华恒生物科技股份有限公司 2025 年第三次临时股东会 会议资料 中国合肥 二〇二五年十一月 安徽华恒生物科技股份有限公司 2025 年第三次临时股东会会议资料 2025 年第三次临时股东会会议资料 目 录 | 2025 年第三次临时股东会会议须知 1 | | --- | | 2025 年第三次临时股东会会议议程 3 | | 议案一：关于选举公司第五届董事会非独立董事的议案 4 | | 议案二：关于选举公司第五届董事会独立董事的议案 5 | 安徽华恒生物科技股份有限公司 2025 年第三次临时股东会会议资料 2025年第三次临时股东会会议须知 为了维护安徽华恒生物科技股份有限公司（以下简称"公司"）全体股东的 合法权益，确保股东会的正常秩序和议事效率，保证股东会的顺利进行，根据《中 华人民共和国公司法》（以下简称"《公司法》"）《中华人民共和国证券法》（以下 简称"《证券法》"）《上市公司股东会规则》以及《安徽华恒生物科技股份有限公 司章程》（以下简称《公司章程》）等相关规定，特制定 2025 ...

Core Viewpoint - The article emphasizes the rising importance of biomanufacturing as a strategic and innovative field that disrupts traditional production methods, presenting it as a new growth point for optimizing industrial structure and transforming economic models. The release of the "2025 China Synthetic Biomanufacturing Industry Development White Paper" highlights the current state, trends, and challenges of the biomanufacturing industry in China [1]. Group 1: Current State and Trends - The white paper outlines the development status and trends of biomanufacturing, analyzing the global landscape and key platform facilities [5]. - It compares the biomanufacturing sectors of China and the United States, identifying competitive advantages and areas for improvement [5]. - Future development trends in biomanufacturing are discussed, indicating a shift towards more integrated and sustainable practices [5]. Group 2: Policy Landscape - The report reviews major policies affecting biomanufacturing both domestically and internationally for the years 2024-2025, providing insights into regulatory frameworks that could impact industry growth [5]. - It categorizes foreign and domestic policies, highlighting their implications for the biomanufacturing sector [5]. Group 3: Industry Map and Applications - A comprehensive map of the Chinese biomanufacturing industry is presented, detailing the key players and their roles within the ecosystem [5]. - The report identifies critical application areas for biomanufacturing, including pharmaceuticals, food, personal care, agriculture, chemicals, materials, and energy [5]. Group 4: Key Enterprises - The white paper lists the top 10 chain leader enterprises in China's biomanufacturing industry, providing a snapshot of the leading companies driving innovation and growth [6]. - It also details the strategic directions of 15 publicly listed companies in the synthetic biology space, summarizing their approaches to market opportunities [6]. Group 5: Investment and Challenges - The report discusses the investment landscape for synthetic biology in China, covering trends and funding activities from 2024 to mid-2025 [6]. - It addresses the challenges faced by the biomanufacturing industry in China, proposing targeted policy recommendations to overcome these obstacles [6].

Investment Rating - The report maintains a "Positive" rating for the chemical industry [4][5]. Core Viewpoints - The chemical industry is experiencing a seasonal demand downturn combined with rising costs, leading to a decline in profitability. However, there are signs of a potential recovery as the cycle approaches a bottom [4][6]. - The report highlights that the overall revenue for the chemical sector in Q3 2025 was 543.8 billion yuan, a year-on-year increase of 4% but a quarter-on-quarter decrease of 1%. Net profit reached 33.6 billion yuan, up 10% year-on-year but down 5% quarter-on-quarter [4][29]. - The report emphasizes the importance of focusing on demand-driven sectors such as the textile and agricultural chains, as well as export-related products, while also considering the benefits from the "anti-involution" policies [4][5]. Summary by Sections 1. Chemical Sector Overview - In Q3 2025, the chemical sector faced a traditional seasonal downturn with reduced downstream operations, leading to a state of inventory reduction. The average price of Brent crude oil was $69.29 per barrel, down 14% year-on-year but up 2% quarter-on-quarter. The average price of thermal coal was approximately 673.10 yuan per ton, down 21% year-on-year but up 5% quarter-on-quarter [4][29]. - The overall gross margin for the chemical sector was 17.6%, with a slight year-on-year increase of 0.4% but a quarter-on-quarter decrease of 0.3% [4][29]. 2. Industry Profitability Under Pressure - The report notes that the profitability of the chemical sector is under pressure due to rising costs and seasonal demand declines. The average asset-liability ratio for the sector is 49.6%, remaining stable year-on-year and slightly down by 0.5% quarter-on-quarter [4][29][35]. - Specific segments such as agricultural chemicals are performing well, with net profit growth in areas like fertilizers and pesticides, while other segments like titanium dioxide and organic silicon are experiencing significant declines [4][5]. 3. Investment Opportunities - The report suggests focusing on sectors with high growth potential, such as the textile chain, agricultural chain, and export-related products. Key companies to watch include Lu Xi Chemical, Tongkun Co., and Wan Hua Chemical [4][5][6]. - The report also highlights the importance of key materials and self-sufficiency in the semiconductor and AI+ sectors, recommending companies like Yake Technology and Dinglong Co. for investment [4][5].

Investment Rating - Industry investment rating: Overweight [1] Core Views - The chemical sector showed a weekly performance ranking of 4th with a gain of 2.50%, outperforming the Shanghai Composite Index by 2.38 percentage points [3][22] - The chemical industry is expected to maintain a differentiated trend in 2025, with recommendations to focus on synthetic biology, pesticides, chromatography media, sweeteners, vitamins, light hydrocarbon chemicals, COC polymers, and MDI [4] Summary by Sections Industry Performance - The chemical sector's overall performance ranked 4th for the week of October 27 to October 31, 2025, with a gain of 2.50% [22] - The top three performing sub-sectors were fluorochemicals (8.40%), inorganic salts (7.68%), and phosphate fertilizers (5.84%) [23] Key Industry Dynamics - A new 510 billion yuan state-owned enterprise fund for emerging industries has been launched, focusing on strategic emerging industries such as new-generation information technology, artificial intelligence, and new materials [34] - The price of lithium hexafluorophosphate continued to rise, with a 15% increase to 103,500 yuan/ton, driven by high demand in the energy storage market [34] Recommendations for Specific Sectors - Synthetic biology is highlighted as a key area for growth, with companies like Kasei Biotech and Huaheng Biotech recommended for investment [4] - The third-generation refrigerants are expected to enter a high prosperity cycle due to quota policies, benefiting companies with high quota shares such as Juhua Co., Sanmei Co., and Haohua Technology [5] - The electronic specialty gases market presents significant domestic substitution opportunities, with companies like Jinhong Gas and Huate Gas positioned for growth [6][8] - Light hydrocarbon chemicals are identified as a global trend, with companies like Satellite Chemical recommended for investment [8] - The COC polymer industry is accelerating its domestic industrialization process, with companies like AkzoNobel expected to benefit [9] - Potash fertilizer prices are anticipated to rebound as supply tightens, with companies like Yara International and Salt Lake Potash recommended [10] - The MDI market is expected to improve due to oligopolistic supply dynamics, with Wanhu Chemical highlighted as a key player [12]

Core Viewpoint - Biobased products are considered "carbon neutral" and are essential for addressing climate change by replacing fossil-based products, especially in the context of dwindling petrochemical resources and global warming [1][5]. Market Overview - The global biobased products market is projected to grow from $22.8 billion in 2020 to $42.1 billion in 2024, with China leading the market at $19.9 billion, accounting for 47.27% of the global share [5][6]. - By 2025, the global market is expected to reach $48.1 billion, with China's share increasing to $23.1 billion, or 48.02% [5][6]. - The market is anticipated to exceed $80 billion within the next five years [5]. Industry Definition and Classification - Biobased products are defined as products derived from biomass (including plants, animals, and microorganisms) or biological processes (such as fermentation) [2]. - They can be categorized into two main types: biobased energy (solid, liquid, and gas forms) and biobased materials (macromolecular and small molecular biochemicals) [2][3]. Industry Chain - The biobased products industry chain includes upstream raw materials (crops, plant waste, and biomass), midstream processing companies that convert these materials into biobased products, and downstream applications in various sectors such as packaging, textiles, and transportation [6][7]. Policy Environment - The Chinese government has implemented various policies to promote the development of biobased products, emphasizing the reduction of fossil resource dependency and the promotion of a green economy [8][9]. Competitive Landscape - The biobased products industry in China is characterized by a diverse and tiered competitive landscape, with key players including Fengbei Bio, Kaisa Bio, Jindan Technology, and Wanhua Chemical [10][11]. - Notable companies like Anhui Huaheng Bio and Shanghai Kaisa Bio have established themselves as leaders in the biobased product sector, focusing on research, production, and sales of biobased materials [11][12]. Development Directions - The increasing global energy demand and the finite nature of conventional energy resources highlight the significance of biobased products as a sustainable alternative [13][14]. - The industry is seen as a crucial pathway towards achieving carbon neutrality, with ongoing technological advancements and cost reductions enhancing market prospects [15].

Investment Rating - The report maintains a "Recommended" rating for the basic chemical industry [1] Core Insights - The "14th Five-Year Plan" has highlighted the need to eliminate "involution" in the chemical industry, which has led to a significant decline in profitability during the previous five years. The new plan aims to create a healthy competitive environment that promotes sustainable high-quality development in the chemical sector [4] - The report emphasizes the transition of China's chemical industry towards a global leadership position, with expectations for continued quality upgrades and increased competitiveness on the global stage during the "15th Five-Year Plan" [4] - The focus on new demands and the development of strategic emerging industries such as new energy and new materials is expected to drive innovation and growth in the chemical sector [4] - The report identifies green and low-carbon initiatives as long-term development directions for the chemical industry, with a focus on clean energy utilization and carbon emission control [4] - Investment opportunities are highlighted in five key areas: improvement of profitability through reduced competition, sustained demand in specific chemical sectors, opportunities in high-end chemical materials, green energy chemical opportunities, and the expansion of Chinese companies in the global market [4][5] Summary by Sections - **Investment Opportunities**: The report suggests focusing on sectors such as polyester filament, organic silicon, pesticides, and spandex, with specific companies like New Fengming, Tongkun, and Jiangshan being highlighted [4] - **Supply and Demand Dynamics**: The report indicates that the supply-demand structure in the chemical industry will be optimized during the "15th Five-Year Plan," presenting a critical historical opportunity for growth [4] - **Emerging Technologies**: The report points out that new technologies related to biomanufacturing and hydrogen energy will be crucial for the development of high-end chemical materials [4]

Investment Rating - Industry Rating: Neutral (maintained rating) [7] Core Views - The chemical raw materials and products manufacturing industry saw a year-on-year investment decline of 5.6% in the first nine months of the year, while industrial investment grew by 6.4% [2][14] - Key price movements include a 6.9% increase in WTI oil prices, with significant price rises in Vitamin E (+11.8%) and sulfur (+11.7%) [3][4] - The basic chemical sector increased by 2.74% over the past week, underperforming the CSI 300 index by 0.5 percentage points [5][17] Summary by Sections 1. Key News Tracking - National Bureau of Statistics reported a total fixed asset investment of 371535 billion yuan, a year-on-year decrease of 0.5% [2][14] - The chemical raw materials and products manufacturing sector's investment fell by 5.6% [2][14] 2. Key Chemical Product Price Monitoring - Among 345 tracked chemical products, 60 saw price increases, while 93 experienced declines [27] - The top five chemical products with price increases include liquid nitrogen (+16.1%), liquid oxygen (+14.3%), and natural gas (+12.8%) [30] 3. Key Individual Stock Tracking - The top-performing stocks in the basic chemical sector include Shilong Industrial (+49.32%) and Nongxin Technology (+27.25%) [22] - The worst-performing stocks include Shanshui Technology (-17.22%) and Chengxing Shares (-14.81%) [24] 4. Sector Valuation - As of October 24, the basic chemical sector's PB ratio is 2.4 times, while the overall A-share market's PB is 1.72 times [25] - The PE ratio for the basic chemical sector stands at 27.86 times compared to the overall A-share market's 17.75 times [25] 5. Focused Sub-industry Insights - Demand stability and global supply dominance are highlighted in sub-industries such as sucralose and pesticides [6] - Recommendations include companies like Jinhai Real Estate and Yunnong Chemical for agricultural chemicals [6]

Core Viewpoint - Huaheng Biological is a leading biomanufacturing company specializing in amino acids and their derivatives, with a focus on R&D, production, and sales in the food and feed additive sector [1] Group 1: Business Performance - For Q3 2025, Huaheng Biological reported revenue of 2.194 billion yuan, ranking 8th in the industry out of 24 companies, with the industry leader, Meihua Biological, generating 18.215 billion yuan [2] - The net profit for the same period was 159 million yuan, placing the company 9th in the industry, while the top performer, Xinheng, achieved a net profit of 5.354 billion yuan [2] - Year-on-year, the company’s revenue increased by 42.5%, while the net profit saw a slight decline of 1.3% [5] Group 2: Financial Ratios - As of Q3 2025, Huaheng Biological's debt-to-asset ratio stood at 52.96%, higher than the industry average of 28.46%, although it has improved from 60.56% in the previous year [3] - The gross profit margin was reported at 23.55%, below the industry average of 28.77%, and down from 28.13% in the previous year, indicating a need for improvement in profitability [3] Group 3: Leadership and Shareholder Information - The chairman and general manager, Guo Henghua, saw her salary increase from 1.026 million yuan in 2023 to 1.754 million yuan in 2024, an increase of 728,000 yuan [4] - As of September 30, 2025, the number of A-share shareholders increased by 23.84% to 10,200, while the average number of shares held per shareholder decreased by 19.25% to 24,500 [5]

Investment Rating - The report maintains a "Buy" rating for the company [8][9][20] Core Views - The company reported a revenue of 21.9 billion yuan for the first three quarters of 2025, representing a year-on-year increase of 42.5%. The net profit attributable to shareholders was 1.7 billion yuan, a slight decrease of 1.3% year-on-year, while the net profit excluding non-recurring items was also 1.7 billion yuan, up 0.8% year-on-year [2][6] - In Q3 alone, the company achieved a revenue of 7.0 billion yuan, which is a 34.7% increase year-on-year but a 12.2% decrease quarter-on-quarter. The net profit attributable to shareholders for Q3 was 0.53 billion yuan, up 161.2% year-on-year but down 17.3% quarter-on-quarter [2][6] - The company is a leading player in the biomanufacturing sector with high technical barriers, and the future release of new products is promising. Projected net profits for 2025-2027 are 2.5 billion, 3.6 billion, and 5.1 billion yuan respectively [8][9] Summary by Sections Financial Performance - For the first three quarters of 2025, the company achieved a total revenue of 21.9 billion yuan, a 42.5% increase year-on-year, and a net profit of 1.7 billion yuan, down 1.3% year-on-year. The net profit excluding non-recurring items was also 1.7 billion yuan, up 0.8% year-on-year [2][6] - In Q3, the company reported a revenue of 7.0 billion yuan, a 34.7% increase year-on-year, and a net profit of 0.53 billion yuan, up 161.2% year-on-year [2][6] Market Dynamics - The average price of refrigerants continued to rise in Q3, with a slight decrease in sales volume quarter-on-quarter. The company sold 76,000 tons of refrigerants in Q3, a decrease of 10.6% year-on-year and 10.3% quarter-on-quarter, with a tax-inclusive average price of 43,000 yuan per ton, up 52.6% year-on-year [7][12] - The company’s profit margins saw a slight decline in Q3, with a gross profit margin of 22.4%, up 1.0 percentage points year-on-year but down 1.6 percentage points quarter-on-quarter [7][12] Future Outlook - The company is expected to benefit from the ongoing growth in the refrigerant industry, with new product launches anticipated to drive future revenue growth. The company is also investing in biobased new materials and has established partnerships to enhance its product offerings [12][8] - The projected revenues for 2025-2027 are 50.3 billion, 67.8 billion, and 86.7 billion yuan respectively, indicating strong growth potential [9][8]

Core Viewpoint - Anhui Huaheng Biotechnology Co., Ltd. has reported significant growth in its financial performance for Q3 2025, indicating strong operational momentum and a focus on research and innovation [1][2] Financial Performance - In Q3, the company's operating revenue reached 704 million yuan, representing a year-on-year increase of 34.73% [1] - The net profit attributable to shareholders was 52.73 million yuan, showing a remarkable year-on-year growth of 161.22% [1] - The net profit after deducting non-recurring gains and losses was 52.21 million yuan, reflecting a year-on-year increase of 187.98% [1] - For the first three quarters, the total operating revenue amounted to 2.194 billion yuan, marking a year-on-year growth of 42.53% [1] Research and Development - The company emphasizes research and innovation, with internal teams focused on market demands and developing cutting-edge synthetic biology technologies [1] - Multiple high-end research platforms have been established, including independent research platforms, strategic cooperation platforms, and joint laboratories with major research institutes and universities [1] - External research teams provide comprehensive support in areas such as strain construction, technology expansion, and innovation management, laying a solid foundation for product innovation and sustainable development [1] Strategic Initiatives - To enhance brand influence and core competitiveness, the company has officially submitted an application for listing on the main board of the Hong Kong Stock Exchange [1] - Successful issuance of H-shares is expected to help the company leverage international capital market resources, optimize capital structure, and broaden financing channels [2] - This move is aligned with the company's global development strategy aimed at achieving stable performance growth [2]